Terns Pharmaceuticals, Inc. (TERN)
| Market Cap | 6.11B +2,817.9% |
| Revenue (ttm) | n/a |
| Net Income | -96.21M |
| EPS | -1.03 |
| Shares Out | 115.46M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 6,344,267 |
| Open | 52.97 |
| Previous Close | 52.93 |
| Day's Range | 52.94 - 52.98 |
| 52-Week Range | 2.66 - 53.19 |
| Beta | -0.38 |
| Analysts | Buy |
| Price Target | 45.22 (-14.6%) |
| Earnings Date | May 14, 2026 |
About TERN
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in Phase 1/2 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced metabolic stability and liver distribution that is in Phase IIa clinical trial for the treatment of metaboli... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 12 analysts, the average rating for TERN stock is "Buy." The 12-month stock price target is $45.22, which is a decrease of -14.60% from the latest price.
News
Merck completes Terns Pharmaceuticals acquisition
Merck (MRK) announced the completion of the acquisition of Terns Pharmaceuticals (TERN). TERN-701 was recently granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration for the...
Merck Completes Acquisition of Terns Pharmaceuticals, Inc.
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the successful completion of the acquisition of Terns Pharmaceuticals, Inc. (“Te...
Merck comments on TERN-701 positive for Enliven’s ELVN-001, says Mizuho
Mizuho reiterated an Outperform rating and $45 price target on Enliven (ELVN) after Merck (MRK) noted during its Q1 call that it believes Terns’ (TERN) TERN-701 major molecular response “will…
Terns Pharmaceuticals granted breakthrough therapy designation for TERN-701
Terns Pharmaceuticals (TERN) announced that the FDA granted breakthrough therapy designation to TERN-701, a novel, oral allosteric BCR::ABL1 inhibitor, for the treatment of adult patients with Ph+ CML...
Terns Pharmaceuticals Announces FDA Breakthrough Therapy Designation Granted to TERN-701 for Certain Patients with Chronic Myeloid Leukemia
Designation for the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in the chronic phase (CP) without the T315I mutation previously treated with tw...
Oppenheimer downgrades Terns Pharmaceuticals to Perform following Merck deal
As previously reported, Oppenheimer downgraded Terns Pharmaceuticals to Perform from Outperform and removed the firm’s price target of $58 on the stock. Oppenheimer says Merck’s (MRK) acquisition of T...
Terns Pharmaceuticals downgraded to Perform from Outperform at Oppenheimer
Oppenheimer downgraded Terns Pharmaceuticals (TERN) to Perform from Outperform after the company agreed to be acquired by Merck (MRK) for $53 per share.
Merck announces expiration of HSR waiting period to acquire Terns Pharmaceuticals
Merck (MRK) announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, in connection with Merck’s pending acquisition of Terns Pharmaceuticals (TERN)...
Merck Announces Expiration of Hart-Scott-Rodino Act Waiting Period to Acquire Terns Pharmaceuticals, Inc.
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act o...
Are TERN, SLNO, WSR Obtaining Fair Deals for their Shareholders?
Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may contain terms that could limit superior competing offers.
Terns Pharmaceuticals downgraded to Market Perform from Outperform at Leerink
Leerink downgraded Terns Pharmaceuticals (TERN) to Market Perform from Outperform after the company agreed to be acquired by Merck (MRK) for $53 per share.
Terns Pharmaceuticals downgraded to Market Perform from Outperform at William Blair
William Blair downgraded Terns Pharmaceuticals (TERN) to Market Perform from Outperform. Following Terns’ filing of its Schedule 14D-9 solicitation/recommendation statement detailing the board’s sale ...
Unusually active option classes on open April 7th
Unusual total active option classes on open include: Virgin Galactic (SPCE), Invesco (IVZ), Terns Parmaceuticles (TERN), UnitedHealth (UNH), Sealsq Corp (LAES), Intel (INTC), AMC Entertainment (AMC), ...
Merck begins tender offer to acquire Terns Pharmaceuticals
Merck (MRK) is commencing today, through a subsidiary, a cash tender offer to purchase all outstanding shares of common stock of Terns Pharmaceuticals (TERN). On March 25, 2026, Merck announced…
Merck Begins Tender Offer to Acquire Terns Pharmaceuticals, Inc.
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, is commencing today, through a subsidiary, a cash tender offer to purchase all outstanding share...
Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)
FOSTER CITY, Calif., April 02, 2026 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage oncology company, today announced that it has granted as...
Terns Pharmaceuticals downgraded to Hold from Buy at Truist
Truist analyst Srikripa Devarakonda downgraded Terns Pharmaceuticals (TERN) to Hold from Buy with a price target of $53, down from $56, after the company agreed to be acquired by Merck…
Terns Pharmaceuticals downgraded to Equal Weight from Overweight at Barclays
Barclays downgraded Terns Pharmaceuticals (TERN) to Equal Weight from Overweight with a $53 price target down from $56, after the company agreed to be acquired by Merck (MRK) for $53…
Terns Pharmaceuticals downgraded to Neutral from Outperform at Mizuho
Mizuho downgraded Terns Pharmaceuticals (TERN) to Neutral from Outperform with a price target of $53, down from $54, after the company agreed to be acquired by Merck (MRK) for $53…
Terns Pharmaceuticals downgraded to Market Perform from Outperform at BMO Capital
BMO Capital analyst Evan Seigerman downgraded Terns Pharmaceuticals (TERN) to Market Perform from Outperform with a $53 price target after the company agreed to be acquired by Merck (MRK) for…
Terns Pharmaceuticals downgraded to Market Perform from Outperform at Citizens
Citizens downgraded Terns Pharmaceuticals (TERN) to Market Perform from Outperform without as price target after the company agreed to be acquired by Merck (MRK) for $53 per share. Published first…
Terns Pharmaceuticals downgraded to Hold from Buy at TD Cowen
TD Cowen analyst Ritu Baral downgraded Terns Pharmaceuticals (TERN) to Hold from Buy with a $53 price target after the company agreed to be acquired by Merck (MRK) for $53…
Merck to buy Terns Pharmaceuticals for $6.7 billion to boost cancer pipeline
Merck is trying to bulk up its portfolio ahead of its best-selling cancer drug Keytruda losing patent protection in 2028.
Merck boosts cancer portfolio with $6.7 billion buyout of Terns Pharma
Merck said on Wednesday it would buy biotech Terns Pharma in a deal valued at up to $6.7 billion, as the drugmaker races to bolster its cancer pipeline ahead of the looming patent loss f...
Merck Reaches Nearly $6 Billion Deal for Cancer Biotech Terns
The drugmaker has been seeking to bolster its pipeline as its top-selling drug, Keytruda, is set to lose patent protection.